Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
Exp Hematol Oncol
; 11(1): 54, 2022 Sep 12.
Article
em En
| MEDLINE
| ID: mdl-36096954
ABSTRACT
Activating G protein-coupled estrogen receptor 1 (GPER1) is an attractive therapeutic strategy for treating a variety of human diseases including cancer. Here, we show that GPER1 is significantly upregulated in tumor cells from different cohorts of Waldenström Macroglobulinemia (WM) patients compared to normal B cells. Using the clinically applicable GPER1-selective small-molecule agonist G-1 (also named Tespria), we found that pharmacological activation of GPER1 leads to G2/M cell cycle arrest and apoptosis both in vitro and in vivo in animal models, even in the context of the protective bone marrow milieu. Activation of GPER1 triggered the TP53 pathway, which remains actionable during WM progression. Thus, this study identifies a novel therapeutic target in WM and paves the way for the clinical development of the GPER1 agonist G-1.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Exp Hematol Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos